Silo Pharma, Inc.(SILO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,875 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
SILO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Silo Pharma, Inc. (SILO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SILO at 13.4/100 on a 32-signal composite quality model, placing it at rank #2,875 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of SILO by reported 13-F value include AdvisorShares Investments, FNY Investment Advisers, CITADEL ADVISORS, based on the most recent SEC filings. SILO trades on the Nasdaq exchange and files with the SEC under CIK 1514183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SILO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Silo Pharma, Inc. directly from SEC EDGAR. Silo Pharma, Inc.'s 13F Pro composite quality score has ranged between 7 and 13 since 2026, currently 13.4 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-832.8K
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+0.0% YoYNet Income
+3.8% YoYOperating Income
+9.0% YoYEPS (Diluted)
+58.0% YoYTotal Assets
+2.6% YoYOp. Cash Flow
-21.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $72.1K +0.0% | $72.1K +0.0% | $72.1K +0.0% | $72.1K | — | $40.9K |
| Net Income | $-4.2M +3.8% | $-4.4M -18.7% | $-3.7M +5.3% | $-3.9M -200.1% | $3.9M +228.5% | $-3.0M |
| Operating Income | $-4.3M +9.0% | $-4.7M -22.0% | $-3.9M -6.3% | $-3.6M -32.2% | $-2.7M -6.7% | $-2.6M |
| EPS (Diluted) | $-0.50 +58.0% | $-1.19 +0.8% | $-1.20 | — | $0.04 +180.0% | $-0.05 |
| Total Assets | $7.6M +2.6% | $7.4M -4.3% | $7.7M -33.5% | $11.6M +11.0% | $10.5M +635.3% | $1.4M |
| Operating Cash Flow | $-4.7M -21.6% | $-3.8M -18.9% | $-3.2M +7.8% | $-3.5M -53.5% | $-2.3M -96.9% | $-1.2M |
Get alerted when SILO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Silo Pharma, Inc. including:
Top Institutional Holders of SILO
AdvisorShares Investments LLC
$469.4K75,582 shFNY Investment Advisers, LLC
$232.0K37,507 shCITADEL ADVISORS LLC
$104.3K16,800 shVANGUARD CAPITAL MANAGEMENT LLC
$74.2K11,956 shVANGUARD FIDUCIARY TRUST CO
$5.4K874 shTower Research Capital LLC (TRC)
$1.1K181 shHARBOUR INVESTMENTS, INC.
$87.0014 shIFP Advisors, Inc
$61.00175 shCITIGROUP INC
$6.001 sh
| Fund | Value | Shares |
|---|---|---|
| AdvisorShares Investments LLC | $469.4K | 75,582 |
| FNY Investment Advisers, LLC | $232.0K | 37,507 |
| CITADEL ADVISORS LLC | $104.3K | 16,800 |
| VANGUARD CAPITAL MANAGEMENT LLC | $74.2K | 11,956 |
| VANGUARD FIDUCIARY TRUST CO | $5.4K | 874 |
| Tower Research Capital LLC (TRC) | $1.1K | 181 |
| HARBOUR INVESTMENTS, INC. | $87.00 | 14 |
| IFP Advisors, Inc | $61.00 | 175 |
| CITIGROUP INC | $6.00 | 1 |
More Healthcare Companies
View all Healthcare →Put SILO on your watchlist
Track score changes the day Silo Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SILO a good stock to buy?
13F Pro's AI-powered analysis of Silo Pharma, Inc. (SILO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SILO are available on the SILO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SILO is classified as a small company.
Which hedge funds own SILO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SILO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Silo Pharma, Inc.'s investment landscape.